Published in Cancer Treat Rev on January 14, 2011
Thiazolidinediones regulate adipose lineage dynamics. Cell Metab (2011) 1.30
Berberine hydrochloride: anticancer activity and nanoparticulate delivery system. Int J Nanomedicine (2011) 0.94
Mesenchymal stem/progenitors and other endometrial cell types from women with polycystic ovary syndrome (PCOS) display inflammatory and oncogenic potential. J Clin Endocrinol Metab (2013) 0.86
Global O-GlcNAc Levels Modulate Transcription of the Adipocyte Secretome during Chronic Insulin Resistance. Front Endocrinol (Lausanne) (2015) 0.82
SIBLINGs and SPARC families: their emerging roles in pancreatic cancer. World J Gastroenterol (2014) 0.80
Quantitative secretome and glycome of primary human adipocytes during insulin resistance. Clin Proteomics (2014) 0.80
Acquisition order of Ras and p53 gene alterations defines distinct adrenocortical tumor phenotypes. PLoS Genet (2012) 0.77
SPARC fusion protein induces cellular adhesive signaling. PLoS One (2013) 0.76
Aberrant methylation of SPARC in human hepatocellular carcinoma and its clinical implication. World J Gastroenterol (2012) 0.76
A p-Median approach for predicting drug response in tumour cells. BMC Bioinformatics (2014) 0.75
Secreted Protein Acidic and Rich in Cysteine (SPARC) Enhances Cell Proliferation, Migration, and Epithelial Mesenchymal Transition, and SPARC Expression is Associated with Tumor Grade in Head and Neck Cancer. Int J Mol Sci (2017) 0.75
SPARC overexpression suppresses radiation-induced HSP27 and induces the collapse of mitochondrial Δψ in neuroblastoma cells. Oncol Lett (2017) 0.75
The fundamental role of epigenetic events in cancer. Nat Rev Genet (2002) 30.05
Angiogenesis in cancer and other diseases. Nature (2000) 28.28
CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci U S A (1999) 13.02
Role of transforming growth factor beta in human disease. N Engl J Med (2000) 10.17
A novel serum protein similar to C1q, produced exclusively in adipocytes. J Biol Chem (1995) 9.72
Adiponectin and adiponectin receptors. Endocr Rev (2005) 8.46
Understanding adipocyte differentiation. Physiol Rev (1998) 6.84
Machine learning approaches for the prediction of signal peptides and other protein sorting signals. Protein Eng (1999) 6.72
Molecular regulation of adipogenesis. Annu Rev Cell Dev Biol (2000) 6.40
CpG island hypermethylation and tumor suppressor genes: a booming present, a brighter future. Oncogene (2002) 5.96
Mitogen-activated protein kinases: specific messages from ubiquitous messengers. Mol Cell Biol (1999) 5.93
Mechanochemical switching between growth and differentiation during fibroblast growth factor-stimulated angiogenesis in vitro: role of extracellular matrix. J Cell Biol (1989) 4.85
Osteonectin, a bone-specific protein linking mineral to collagen. Cell (1981) 4.06
Fibronectin controls capillary endothelial cell growth by modulating cell shape. Proc Natl Acad Sci U S A (1990) 3.18
SPARC, a matricellular protein that functions in cellular differentiation and tissue response to injury. J Clin Invest (2001) 3.13
A prospective study of obesity and cancer risk (Sweden). Cancer Causes Control (2001) 3.13
Meat consumption and risk of colorectal cancer: a meta-analysis of prospective studies. Int J Cancer (2006) 3.06
Invadopodia: specialized cell structures for cancer invasion. Clin Exp Metastasis (2006) 3.05
How does extracellular matrix control capillary morphogenesis? Cell (1989) 2.84
Wnt signaling stimulates osteoblastogenesis of mesenchymal precursors by suppressing CCAAT/enhancer-binding protein alpha and peroxisome proliferator-activated receptor gamma. J Biol Chem (2007) 2.69
Extracellular proteins that modulate cell-matrix interactions. SPARC, tenascin, and thrombospondin. J Biol Chem (1991) 2.47
SPARC/osteonectin is a frequent target for aberrant methylation in pancreatic adenocarcinoma and a mediator of tumor-stromal interactions. Oncogene (2003) 2.32
The biology of SPARC, a protein that modulates cell-matrix interactions. FASEB J (1994) 2.22
SPARC, a secreted protein associated with cellular proliferation, inhibits cell spreading in vitro and exhibits Ca+2-dependent binding to the extracellular matrix. J Cell Biol (1989) 2.10
Characterization of a novel serum albumin-binding glycoprotein secreted by endothelial cells in culture. J Biol Chem (1984) 2.01
Blockade of nuclear factor-kappaB signaling inhibits angiogenesis and tumorigenicity of human ovarian cancer cells by suppressing expression of vascular endothelial growth factor and interleukin 8. Cancer Res (2000) 1.98
The extracellular glycoprotein SPARC interacts with platelet-derived growth factor (PDGF)-AB and -BB and inhibits the binding of PDGF to its receptors. Proc Natl Acad Sci U S A (1992) 1.94
SPARC, a matricellular glycoprotein with important biological functions. J Histochem Cytochem (1999) 1.93
Molecular signatures of metaplastic carcinoma of the breast by large-scale transcriptional profiling: identification of genes potentially related to epithelial-mesenchymal transition. Oncogene (2007) 1.86
An RNA polymerase II construct synthesizes short-hairpin RNA with a quantitative indicator and mediates highly efficient RNAi. Nucleic Acids Res (2005) 1.83
SPARC (secreted protein acidic and rich in cysteine) induces apoptosis in ovarian cancer cells. Am J Pathol (2001) 1.76
Suppression of SPARC expression by antisense RNA abrogates the tumorigenicity of human melanoma cells. Nat Med (1997) 1.76
SPARC (BM-40, osteonectin) inhibits the mitogenic effect of vascular endothelial growth factor on microvascular endothelial cells. J Biol Chem (1998) 1.74
MicroRNA-199b-5p impairs cancer stem cells through negative regulation of HES1 in medulloblastoma. PLoS One (2009) 1.73
Meta-analysis of colorectal cancer gene expression profiling studies identifies consistently reported candidate biomarkers. Cancer Epidemiol Biomarkers Prev (2008) 1.72
In vivo expression of mRNA for the Ca++-binding protein SPARC (osteonectin) revealed by in situ hybridization. J Cell Biol (1987) 1.70
SPARC in cancer biology: its role in cancer progression and potential for therapy. Drug Resist Updat (2008) 1.65
Survey of differentially methylated promoters in prostate cancer cell lines. Neoplasia (2005) 1.63
SPARC inhibits epithelial cell proliferation in part through stimulation of the transforming growth factor-beta-signaling system. Mol Biol Cell (2003) 1.63
Genome-wide expression analysis of therapy-resistant tumors reveals SPARC as a novel target for cancer therapy. J Clin Invest (2005) 1.58
Distribution of SPARC in normal and neoplastic human tissue. J Histochem Cytochem (1995) 1.55
Secreted protein acidic and rich in cysteine promotes glioma invasion and delays tumor growth in vivo. Cancer Res (2002) 1.55
Novel function of alternatively activated macrophages: stabilin-1-mediated clearance of SPARC. J Immunol (2006) 1.53
Differential expression of osteonectin/SPARC during human prostate cancer progression. Clin Cancer Res (2000) 1.52
SPARC endogenous level, rather than fibroblast-produced SPARC or stroma reorganization induced by SPARC, is responsible for melanoma cell growth. J Invest Dermatol (2007) 1.51
The Ca2(+)-binding glycoprotein SPARC modulates cell cycle progression in bovine aortic endothelial cells. Proc Natl Acad Sci U S A (1991) 1.51
Changes in integrin expression during adipocyte differentiation. Cell Metab (2005) 1.51
SPARC-null mice exhibit accelerated cutaneous wound closure. J Histochem Cytochem (2002) 1.47
SPARC is a key Schwannian-derived inhibitor controlling neuroblastoma tumor angiogenesis. Cancer Res (2002) 1.47
The role of the matricellular protein SPARC in the dynamic interaction between the tumor and the host. Cancer Metastasis Rev (2008) 1.45
Functional mapping of SPARC: peptides from two distinct Ca+(+)-binding sites modulate cell shape. J Cell Biol (1990) 1.44
Low or absent SPARC expression in acute myeloid leukemia with MLL rearrangements is associated with sensitivity to growth inhibition by exogenous SPARC protein. Leukemia (2006) 1.42
Calcium binding domains and calcium-induced conformational transition of SPARC/BM-40/osteonectin, an extracellular glycoprotein expressed in mineralized and nonmineralized tissues. Biochemistry (1987) 1.42
Macrophage-secreted factors promote a profibrotic phenotype in human preadipocytes. Mol Endocrinol (2008) 1.41
Retracted Aberrant methylation of SPARC in human lung cancers. Br J Cancer (2005) 1.40
SPARC regulates the expression of collagen type I and transforming growth factor-beta1 in mesangial cells. J Biol Chem (1999) 1.40
SPARC is a source of copper-binding peptides that stimulate angiogenesis. J Cell Biol (1994) 1.40
Aberrant CpG island hypermethylation of multiple genes in colorectal neoplasia. Lab Invest (2004) 1.38
Osteonectin-null mutation compromises osteoblast formation, maturation, and survival. Endocrinology (2003) 1.37
Structural basis of sequence-specific collagen recognition by SPARC. Proc Natl Acad Sci U S A (2008) 1.35
SPARC inhibits adipogenesis by its enhancement of beta-catenin signaling. J Biol Chem (2008) 1.34
SPARC mediates focal adhesion disassembly in endothelial cells through a follistatin-like region and the Ca(2+)-binding EF-hand. J Cell Biochem (1995) 1.32
SPARC represses E-cadherin and induces mesenchymal transition during melanoma development. Cancer Res (2006) 1.31
Cleavage of the matricellular protein SPARC by matrix metalloproteinase 3 produces polypeptides that influence angiogenesis. J Biol Chem (2003) 1.30
Regulation of death receptor-mediated apoptosis pathways. Int J Biochem Cell Biol (2001) 1.30
Targeting SPARC expression decreases glioma cellular survival and invasion associated with reduced activities of FAK and ILK kinases. Oncogene (2007) 1.30
The expression of the secreted protein acidic and rich in cysteine (SPARC) is associated with the neoplastic progression of human melanoma. J Invest Dermatol (1997) 1.30
SPARC: a signal of astrocytic neoplastic transformation and reactive response in human primary and xenograft gliomas. J Neuropathol Exp Neurol (1998) 1.27
The extracellular regulation of growth factor action. Mol Biol Cell (1992) 1.25
The C-terminal portion of BM-40 (SPARC/osteonectin) is an autonomously folding and crystallisable domain that binds calcium and collagen IV. J Mol Biol (1995) 1.24
SPARC antagonizes the effect of basic fibroblast growth factor on the migration of bovine aortic endothelial cells. J Cell Biochem (1992) 1.23
SPARC promoter hypermethylation in colorectal cancers can be reversed by 5-Aza-2'deoxycytidine to increase SPARC expression and improve therapy response. Br J Cancer (2008) 1.23
SPARC modulates cell growth, attachment and migration of U87 glioma cells on brain extracellular matrix proteins. J Neurooncol (2001) 1.23
Absence of host-secreted protein acidic and rich in cysteine (SPARC) augments peritoneal ovarian carcinomatosis. Am J Pathol (2005) 1.22
SPARC (osteonectin/BM-40). Int J Biochem Cell Biol (1999) 1.20
SPARC expression is associated with impaired tumor growth, inhibited angiogenesis and changes in the extracellular matrix. Int J Cancer (2006) 1.20
Limited cleavage of extracellular matrix protein BM-40 by matrix metalloproteinases increases its affinity for collagens. J Biol Chem (1997) 1.18
Endogenous osteonectin/SPARC/BM-40 expression inhibits MDA-MB-231 breast cancer cell metastasis. Cancer Res (2005) 1.16
Regulation of angiogenesis by SPARC and angiostatin: implications for tumor cell biology. Semin Cancer Biol (1996) 1.16
Normalization of the ovarian cancer microenvironment by SPARC. Mol Cancer Res (2007) 1.13
Clinical significance of secreted protein acidic and rich in cystein in esophageal carcinoma and its relation to carcinoma progression. Cancer (2003) 1.12
Signaling pathways in medulloblastoma. J Cell Physiol (2008) 1.12
Endothelial cell injury in vitro is associated with increased secretion of an Mr 43,000 glycoprotein ligand. J Cell Physiol (1986) 1.12
Disruption of the Sparc locus in mice alters the differentiation of lenticular epithelial cells and leads to cataract formation. Exp Eye Res (1999) 1.12
TGF-beta 1 induces the expression of type I collagen and SPARC, and enhances contraction of collagen gels, by fibroblasts from young and aged donors. J Cell Physiol (1994) 1.11
Transcriptional upregulation of SPARC, in response to c-Jun overexpression, contributes to increased motility and invasion of MCF7 breast cancer cells. Oncogene (2002) 1.11
Forced expression of MMP9 rescues the loss of angiogenesis and abrogates metastasis of pancreatic tumors triggered by the absence of host SPARC. Exp Biol Med (Maywood) (2008) 1.08
Inhibition of PDGF-stimulated and matrix-mediated proliferation of human vascular smooth muscle cells by SPARC is independent of changes in cell shape or cyclin-dependent kinase inhibitors. J Cell Biochem (2002) 1.08
SPARC and Hevin expression correlate with tumour angiogenesis in hepatocellular carcinoma. J Pathol (2006) 1.07
Expression of SPARC during development of the chicken chorioallantoic membrane: evidence for regulated proteolysis in vivo. Mol Biol Cell (1995) 1.06
A novel interaction between procaspase 8 and SPARC enhances apoptosis and potentiates chemotherapy sensitivity in colorectal cancers. J Biol Chem (2007) 1.06
SPARC-induced increase in glioma matrix and decrease in vascularity are associated with reduced VEGF expression and secretion. Int J Cancer (2008) 1.06
Relationship and prognostic significance of SPARC and VEGF protein expression in colon cancer. J Exp Clin Cancer Res (2010) 1.06
Regulation of human monocyte matrix metalloproteinases by SPARC. J Cell Physiol (1997) 1.05
Cell cycle-dependent nuclear location of the matricellular protein SPARC: association with the nuclear matrix. J Cell Biochem (1999) 1.05
Doxycycline-inducible expression of SPARC/Osteonectin/BM40 in MDA-MB-231 human breast cancer cells results in growth inhibition. Breast Cancer Res Treat (2002) 1.04
Secreted protein acidic, rich in cysteine (SPARC), mediates cellular survival of gliomas through AKT activation. J Biol Chem (2004) 1.04
HSP27 mediates SPARC-induced changes in glioma morphology, migration, and invasion. Glia (2008) 1.01
Alternatively activated macrophages regulate extracellular levels of the hormone placental lactogen via receptor-mediated uptake and transcytosis. J Immunol (2008) 0.98
Concomitant activation of the JAK/STAT, PI3K/AKT, and ERK signaling is involved in leptin-mediated promotion of invasion and migration of hepatocellular carcinoma cells. Cancer Res (2007) 2.50
Regulation of estrogen receptor alpha by the SET7 lysine methyltransferase. Mol Cell (2008) 2.35
Bidirectional crosstalk between leptin and insulin-like growth factor-I signaling promotes invasion and migration of breast cancer cells via transactivation of epidermal growth factor receptor. Cancer Res (2008) 1.67
A coregulatory role for the TRAP-mediator complex in androgen receptor-mediated gene expression. J Biol Chem (2002) 1.66
Honokiol activates AMP-activated protein kinase in breast cancer cells via an LKB1-dependent pathway and inhibits breast carcinogenesis. Breast Cancer Res (2012) 1.65
leptin-induced growth stimulation of breast cancer cells involves recruitment of histone acetyltransferases and mediator complex to CYCLIN D1 promoter via activation of Stat3. J Biol Chem (2007) 1.48
Leptin-induced epithelial-mesenchymal transition in breast cancer cells requires β-catenin activation via Akt/GSK3- and MTA1/Wnt1 protein-dependent pathways. J Biol Chem (2012) 1.37
A novel histone deacetylase inhibitor, scriptaid, enhances expression of functional estrogen receptor alpha (ER) in ER negative human breast cancer cells in combination with 5-aza 2'-deoxycytidine. Breast Cancer Res Treat (2003) 1.32
Adiponectin modulates C-jun N-terminal kinase and mammalian target of rapamycin and inhibits hepatocellular carcinoma. Gastroenterology (2010) 1.20
Reciprocal regulation of ZEB1 and AR in triple negative breast cancer cells. Breast Cancer Res Treat (2009) 1.15
Med1 plays a critical role in the development of tamoxifen resistance. Carcinogenesis (2012) 1.13
Activation of TRAP/mediator subunit TRAP220/Med1 is regulated by mitogen-activated protein kinase-dependent phosphorylation. Mol Cell Biol (2005) 1.13
Benzyl isothiocyanate inhibits oncogenic actions of leptin in human breast cancer cells by suppressing activation of signal transducer and activator of transcription 3. Carcinogenesis (2010) 1.04
Survivin upregulation, dependent on leptin-EGFR-Notch1 axis, is essential for leptin-induced migration of breast carcinoma cells. Endocr Relat Cancer (2011) 1.01
Interaction of an approximately 40 kDa protein from regenerating rat liver with the -148 to -124 region of c-jun complexed with RLjunRP coincides with enhanced c-jun expression in proliferating rat liver. Eur J Biochem (2004) 0.91
Multifaceted leptin network: the molecular connection between obesity and breast cancer. J Mammary Gland Biol Neoplasia (2013) 0.88
Mechanistic elucidation of the antitumor properties of withaferin a in breast cancer. Cancer Res (2014) 0.87
Epigenetic Reactivation of Estrogen Receptor: Promising Tools for Restoring Response to Endocrine Therapy. Mol Cell Pharmacol (2010) 0.87
Integral role of PTP1B in adiponectin-mediated inhibition of oncogenic actions of leptin in breast carcinogenesis. Neoplasia (2013) 0.83
Metastasis suppression by adiponectin: LKB1 rises up to the challenge. Cell Adh Migr (2010) 0.80
Comprehensive Evaluation of Anti-hyperglycemic Activity of Fractionated Momordica charantia Seed Extract in Alloxan-Induced Diabetic Rats. Evid Based Complement Alternat Med (2012) 0.79
Modulation of c-myc and c-fos gene expression in regenerating rat liver by 2-mercaptopropionylglycine. Cell Biol Int (2002) 0.78